Combining new and standard biopsy techniques may detect more treatable lung cancer cases, Main Line Health researchers find

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A study by Main Line Health researchers indicates that simultaneously conducting a liquid biopsy and standard tissue biopsy increases the chances of detecting such mutations and is practical for wide usage by hospitals.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

A recent OncoHost study provides insight in understanding resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer. Through a comprehensive bioinformatic analysis of pretreatment plasma proteomic profiles from 272 NSCLC patients, researchers identified key biological processes associated with resistance and revealed therapeutic targets that could inform future precision treatment strategies.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login